Last reviewed · How we verify
MPL-001 (CBD: THC 25:1)
MPL-001 is a cannabinoid combination product that modulates endocannabinoid signaling through CBD and THC at a 25:1 ratio to produce therapeutic effects.
At a glance
| Generic name | MPL-001 (CBD: THC 25:1) |
|---|---|
| Sponsor | McMaster University |
| Drug class | Cannabinoid combination |
| Target | CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The drug combines cannabidiol (CBD) and tetrahydrocannabinol (THC) in a fixed 25:1 ratio. CBD acts as a partial agonist at CB1 and CB2 receptors and modulates serotonin and vanilloid receptors, while THC is a CB1/CB2 agonist. The high CBD-to-THC ratio is designed to maximize therapeutic benefits while minimizing psychoactive effects associated with THC.
Approved indications
Common side effects
- Dizziness
- Fatigue
- Dry mouth
- Altered appetite
Key clinical trials
- Improving Pain Disability With the Use of Oral Cannabinoids (NA)
- CANnabinoids in Pediatric ONCology (PHASE1, PHASE2)
- Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MPL-001 (CBD: THC 25:1) CI brief — competitive landscape report
- MPL-001 (CBD: THC 25:1) updates RSS · CI watch RSS
- McMaster University portfolio CI